Payment overview · 2025
General Payments
$1,150.84
59 reported records · 14 companies
Healthcare provider profile · identity verified
Steven Wayne Ditto, MD
Allopathic & Osteopathic Physicians|Family Medicine · DEL CITY, OK · NPI 1568455772
Verified facts
What the public records show
CMS Open Payments records show Steven Wayne Ditto, MD received $1,150.84 in general payments during 2025 across 59 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $329.36 | 28.6% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $256.02 | 22.2% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $181.83 | 15.8% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $83.35 | 7.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.93 | 5.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.20 | 4.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.12 | 3.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.02 | 2.8% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.52 | 2.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.05 | 1.9% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $20.10 | 1.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.76 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.27 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.31 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,150.84 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $234.89 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $233.43 | 9 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $181.83 | 11 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $176.71 | 10 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $166.81 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.20 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $83.35 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $67.01 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $61.98 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.20 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.02 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $20.14 | 2 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $20.14 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $7.30 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $7.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 126 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 345 | 100 |
| Omeprazole | Omeprazole | 320 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 90 |
| Lisinopril | Lisinopril | 303 | 78 |
| Gabapentin | Gabapentin | 247 | 71 |
| Metformin Hcl | Metformin Hcl | 234 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 60 |
| Losartan Potassium | Losartan Potassium | 150 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 54 |
| Ozempic | Semaglutide | 126 | 27 |
| Meloxicam | Meloxicam | 123 | 39 |
| Potassium Chloride | Potassium Chloride | 122 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 30 |
| Famotidine | Famotidine | 113 | 32 |
| Furosemide | Furosemide | 105 | 29 |
| Allopurinol | Allopurinol | 104 | 28 |
| Trazodone Hcl | Trazodone Hcl | 102 | 28 |
| Carvedilol | Carvedilol | 100 | 28 |
| Montelukast Sodium | Montelukast Sodium | 100 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 32 |
| Buspirone Hcl | Buspirone Hcl | 90 | 19 |
| Glipizide | Glipizide | 83 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 70 | 20 |
| Celecoxib | Celecoxib | 66 | 20 |
| Methocarbamol | Methocarbamol | 62 | 19 |
| Pregabalin | Pregabalin | 59 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 20 |
| Finasteride | Finasteride | 58 | 21 |
| Simvastatin | Simvastatin | 57 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 15 |
| Memantine Hcl | Memantine Hcl | 54 | 18 |
| Sertraline Hcl | Sertraline Hcl | 52 | 14 |
| Tramadol Hcl | Tramadol Hcl | 52 | 19 |
| Propranolol Hcl | Propranolol Hcl | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 12 |
| Donepezil Hcl | Donepezil Hcl | 47 | 18 |
| Eliquis | Apixaban | 45 | 13 |
| Jardiance | Empagliflozin | 45 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 14 |
| Azithromycin | Azithromycin | 44 | 38 |
| Ibuprofen | Ibuprofen | 40 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | 21 |
| Glipizide Er | Glipizide | 37 | 12 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Prednisone | Prednisone | 36 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 11 |
| Linzess | Linaclotide | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | 11 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Topiramate | Topiramate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Mupirocin | Mupirocin | 19 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,150.84 · 59 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BEXSERO, BEYFORTUS, BREZTRI, COMIRNATY, Cologuard Collection Kit, ENFLONSIA, FARXIGA, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, Kerendia, OTEZLA, Ozempic, PEDIARIX, PENBRAYA, PENMENVY, PREVNAR 20, QULIPTA, QUTENZA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, TRUMENBA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VAXNEUVANCE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error